![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Coadministration of Ritonavir with the HCV Protease Inhibitor Danoprevir Substantially Reduces
Reactive Metabolite Formation Both In Vitro and In Vivo
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
P. Goelzer,1 P.N. Morcos,1 J.Q. Tran,2 B. Wen,1 N.S. Shulman,3 B.J. Brennan,1 J. Hammond,1 T. Singer,4 P. Smith1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Hoffmann-La Roche Inc. Palo Alto, CA, USA; 3Genentech, South San Francisco, CA, USA; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland
![AASLD1.gif](../images/112612/112612-3/AASLD1.gif)
![AASLD2.gif](../images/112612/112612-3/AASLD2.gif)
![AASLD3.gif](../images/112612/112612-3/AASLD3.gif)
![AASLD4.gif](../images/112612/112612-3/AASLD4.gif)
![AASLD5.gif](../images/112612/112612-3/AASLD5.gif)
![AASLD6.gif](../images/112612/112612-3/AASLD6.gif)
![AASLD7.gif](../images/112612/112612-3/AASLD7.gif)
![AASLD8.gif](../images/112612/112612-3/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|